statistiche ricercatore

TANDA, MARIA LAURA PIERA

Distribuzione geografica

Continente	#
NA - Nord America	14.626
EU - Europa	7.061
AS - Asia	5.673
SA - Sud America	694
AF - Africa	129
OC - Oceania	16
Continente sconosciuto - Info sul continente non disponibili	15
AN - Antartide	1
Totale	28.215

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	14.411
IT - Italia	3.310
SG - Singapore	1.820
CN - Cina	1.334
UA - Ucraina	868
VN - Vietnam	777
HK - Hong Kong	620
SE - Svezia	609
BR - Brasile	549
DE - Germania	476
TR - Turchia	451
FI - Finlandia	330
IE - Irlanda	323
GB - Regno Unito	320
FR - Francia	275
BD - Bangladesh	231
RU - Federazione Russa	194
IN - India	126
CA - Canada	109
JP - Giappone	94
MX - Messico	83
PL - Polonia	60
AR - Argentina	49
NL - Olanda	47
NG - Nigeria	46
AT - Austria	43
CZ - Repubblica Ceca	37
ES - Italia	33
ZA - Sudafrica	33
IQ - Iraq	28
MY - Malesia	25
EC - Ecuador	24
BE - Belgio	23
CL - Cile	22
CH - Svizzera	21
LT - Lituania	20
PK - Pakistan	19
ID - Indonesia	18
AE - Emirati Arabi Uniti	15
IL - Israele	15
EU - Europa	14
UZ - Uzbekistan	14
CO - Colombia	11
NP - Nepal	11
RO - Romania	11
VE - Venezuela	11
PH - Filippine	10
KR - Corea	9
MA - Marocco	9
MD - Moldavia	9
PE - Perù	9
PY - Paraguay	9
SA - Arabia Saudita	9
AU - Australia	8
JO - Giordania	8
NZ - Nuova Zelanda	8
KE - Kenya	7
MT - Malta	7
TN - Tunisia	7
DZ - Algeria	6
EG - Egitto	6
JM - Giamaica	6
TH - Thailandia	6
KG - Kirghizistan	5
PT - Portogallo	5
BG - Bulgaria	4
BO - Bolivia	4
BY - Bielorussia	4
CR - Costa Rica	4
HU - Ungheria	4
MK - Macedonia	4
TW - Taiwan	4
UY - Uruguay	4
AZ - Azerbaigian	3
BA - Bosnia-Erzegovina	3
CI - Costa d'Avorio	3
DK - Danimarca	3
DO - Repubblica Dominicana	3
HR - Croazia	3
IR - Iran	3
KZ - Kazakistan	3
RS - Serbia	3
SN - Senegal	3
AL - Albania	2
BH - Bahrain	2
CG - Congo	2
EE - Estonia	2
ET - Etiopia	2
GR - Grecia	2
GT - Guatemala	2
HN - Honduras	2
KW - Kuwait	2
NI - Nicaragua	2
SK - Slovacchia (Repubblica Slovacca)	2
SR - Suriname	2
SV - El Salvador	2
A2 - ???statistics.table.value.countryCode.A2???	1
AM - Armenia	1
AO - Angola	1
AQ - Antartide	1
Totale	28.195

Salva come PNG Salva come JPEG

Città	#
Milan	2.102
Fairfield	1.409
Ashburn	1.277
Dallas	1.231
San Jose	1.167
Singapore	1.045
Woodbridge	831
Chandler	737
Jacksonville	684
Houston	674
Hong Kong	603
Seattle	569
Wilmington	527
Cambridge	451
Dearborn	367
Ann Arbor	354
Nyköping	322
Beijing	317
Dublin	306
Princeton	302
The Dalles	234
Izmir	216
Boardman	213
Rome	193
Council Bluffs	188
Lauterbourg	184
Chicago	182
New York	173
Los Angeles	168
Dong Ket	164
Ho Chi Minh City	135
Helsinki	132
Hanoi	114
Como	105
San Diego	102
London	96
Santa Clara	89
San Mateo	78
Tokyo	77
São Paulo	75
Munich	74
Orem	74
Guangzhou	66
Ogden	60
Washington	59
Frankfurt am Main	53
Warsaw	51
Shanghai	50
Redmond	48
Mexico City	46
Abuja	45
Buffalo	43
Chennai	43
Hefei	41
Phoenix	41
Montreal	38
Varese	37
Denver	35
Toronto	35
Brno	33
Kunming	33
Manchester	31
San Francisco	29
Atlanta	28
Düsseldorf	26
Haiphong	26
Vienna	26
Johannesburg	25
Nuremberg	25
Poplar	25
Brooklyn	23
Turku	23
Brussels	22
Salt Lake City	22
Amsterdam	21
Nanjing	21
Norwalk	21
Stockholm	21
Paris	20
Shenzhen	20
Cavaria con Premezzo	19
Da Nang	18
Hangzhou	18
Tianjin	18
Belo Horizonte	17
Berlin	17
Jinan	17
North Bergen	17
Tampa	17
Naples	16
Boston	15
Istanbul	15
Las Vegas	15
Turin	15
Charlotte	14
Elk Grove Village	14
Kuala Lumpur	14
Mumbai	14
Zhengzhou	14
Ankara	13
Totale	19.970

Salva come PNG Salva come JPEG

Nome	#
The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy	327
Iopanoic acid rapidly controls Type I amiodarone-induced thyrotoxicosis prior to thyroidectomy	273
Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma	263
Graves' ophthalmopathy	263
Simultaneous medullary and papillary thyroid cancer: two case reports.	255
Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study	254
Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved?	253
The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study	251
Epidemiology, natural history, risk factors, and prevention of graves’ orbitopathy	250
Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management	248
Masked hypertension in newly diagnosed hypothyroidism: a pilot study	247
Cardiometabolic healthy and unhealthy obesity: does vitamin D play a role?	239
Disease heterogeneity in IgG4-related hypophysitis: report of two histopathologically proven cases and review of the literature	231
Breast cancer and thyroid diseases: analysis of 867 consecutive cases	229
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study	228
The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study	221
Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review	220
Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European Endocrinologists	219
Pituitary apoplexy during pregnancy: A rare, but dangerous headache	216
Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity	216
Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?	215
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial	214
Amiodarone-unduced thyrotoxicosis. A review	214
Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?	213
Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study	210
Multidisciplinary Management of Intrathoracic Goiter: A Case Report	209
Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe	209
Outcome prediction of treatment of Graves' hyperthyroidism with antithyroid drugs	208
Can a patient-tailored treatment approach for Graves' disease reduce mortality?	208
Nutrizione iodica e ipertiroidismo: quello che c’è da sapere	207
Continuous monitoring of the recurrent laryngeal nerve in thyroid surgery: a critical appraisal	206
Thyroid cancer with tracheal invasion: A pathological estimation	203
Thyroid hormone treatment for differentiated thyroid carcinoma: What drug, how long, what dose?	202
Time interval in diagnosis and treatment of papillary thyroid cancer: a descriptive, retrospective study	201
Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study	200
Minimally invasive follicular thyroid cancer (MIFTC) - A consensus report of the European Society of Endocrine Surgeons (ESES)	200
Physical performance in newly diagnosed hypothyroidism: a pilot study	199
Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH)	198
Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal	197
Case report: multiple electrolyte disturbance with severe neurological manifestations induced by chronic use of PPIs	196
Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association	196
Plasma total and acylated ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction	196
Novel treatment modalities for Graves' orbitopathy	193
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment	193
Skeletal health in patients with differentiated thyroid carcinoma	192
An update on medical management of Graves' ophthalmopathy	190
Medullary thyroid carcinoma: surgical treatment advances	190
Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group	188
Iodine supplementation in women of reproductive age: a survey of clinical practice among Italian gynecologists and midwives	186
Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center	182
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.	181
Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels:studies in vivo by color flow Doppler sonography	180
Shortening Hospital Stay for Thyroid Surgery.	175
Gastric Xanthomatous Hyperplastic Polyps – Just an Incidental Endoscopic Finding?	175
Orbital radiotherapy for Graves' ophthalmopathy	174
Medullary thyroid carcinoma: surgical treatment advances	172
Analisi dei costi	172
Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study	171
Vitamin D, Chronic Migraine, and Extracranial Pain: Is There a Link? Data From an Observational Study	171
Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy	170
Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy	169
An update on the pharmacological management of hyperthyroidism due to Graves' disease	169
Pituitary in black—hypopituitarism secondary to hemosiderosis	169
Relationship between management of hyperthyroidism and course of the ophthalmopathy	166
Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature	166
Amiodarone and the thyroid	164
Amyloid goiter	164
Immunomodulatory role of vitamin D and selenium supplementation in newly diagnosed Graves' disease patients during methimazole treatment	164
Treating Graves' orbitopathy: where are we?	163
Changes in Autonomic Modulation to the Heart and Intracellular Catecholamines. A Longitudinal Study in Differentiated Thyroid Carcinoma during Short-Term Hypothyroidism and Thyroid Hormone Replacement.	162
Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations	162
Radioiodine and thyroid-associated ophthalmopathy	162
A potential role of human RNASET2 overexpression in the pathogenesis of Graves’ disease	162
Oxidative stress and Graves' ophthalmopathy: In vitro studies and therapeutic implications	161
Management of thyroid eye disease	160
Thyroid autoimmunity and environment	160
Orbital radiotherapy for Graves' ophthalmopathy	159
Efficacy and safety of orbital radiotherapy for Graves' orbitopathy	159
Endpoints for screening thyroid cancer in the Republic of Korea: thyroid specialists' perspectives.	159
Relation between Graves' orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions	158
Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis?	154
Novel approaches to the management of Graves' ophthalmopathy	154
Recent developments in the follow-up, prevention and management of complications in thyroid surgery	154
Cigarette smoking and the thyroid	152
La prevenzione dell'oftalmopatia basedowiana	151
Orbital radiotherapy for Graves' ophthalmopathy	150
Cigarette smoking and treatment outcomes in Graves' ophthalmopathy	150
Smoking and the Thyroid	150
When primary hyperparathyroidism comes as good news	150
Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying	149
Orbital decompression in Graves' ophthalmopathy by medial and lateral wall removal	148
Position statement of the Microbiota International Clinical Society	147
Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression	147
Novel immunomodulating agents for Graves orbitopathy	146
Prevalence and natural history of Graves' orbitopathy in the XXI century	146
Solitary intrathyroidal metastasis of renal clear cell carcinoma in a toxic substernal multinodular goiter.	146
Currently available somatostatin analogs are not good for Graves' orbitopathy	144
Severità del Morbo di Basedow di prima diagnosi: ruolo dei linfociti Treg e dei micronutrienti. Dati preliminari di uno studio osservazionale pilota	144
Image-guided thyroid nodule ablation: technical notes and critical appraisal	143
SARS-CoV-2 vaccine-associated subacute thyroiditis: insights from a systematic review	138
Totale	18.880

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	117.152
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	117.152

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	368	0	0	0	0	0	0	0	0	0	0	0	368
2021/2022	1.829	176	169	89	71	111	139	117	88	246	291	128	204
2022/2023	2.201	272	139	170	230	158	486	16	265	264	82	52	67
2023/2024	3.560	531	536	544	653	643	333	19	41	95	46	17	102
2024/2025	2.905	14	26	435	126	100	145	135	210	306	230	366	812
2025/2026	9.649	624	737	998	1.184	800	484	1.791	581	859	637	566	388
Totale													28.530